TMO
Thermo Fisher Scientific Inc.
- Operating cash flow, 2025
- $7.8B
- YoY, 2025
- −9.8%
- 5-year CAGR
- −1.2%
- 10-year CAGR
- +10.3%
Operating cash flow
Operating cash flow by fiscal year
| Period | Operating cash flow | YoY |
|---|---|---|
| 2025 | $7.8B | −9.8% |
| 2024 | $8.7B | +3.1% |
| 2023 | $8.4B | −8.2% |
| 2022 | $9.2B | −1.7% |
| 2021 | $9.3B | +12.3% |
| 2020 | $8.3B | +66.7% |
| 2019 | $5.0B | +9.5% |
| 2018 | $4.5B | +13.4% |
| 2017 | $4.0B | +22.9% |
| 2016 | $3.3B | +10.7% |
| 2015 | $2.9B | +12.3% |
| 2014 | $2.6B | +30.3% |
| 2013 | $2.0B | −1.4% |
| 2012 | $2.0B | +20.6% |
| 2011 | $1.7B | +12.9% |
| 2010 | $1.5B | −9.7% |
| 2009 | $1.7B | +16.8% |
| 2008 | $1.4B | −4.3% |
| 2007 | $1.5B | — |